Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma

October 1, 2014 Immunovaccine Inc. (“Immunovaccine” or “IMV”), a clinical stage vaccine and immunotherapy company, today provided a clinical development program update for DPX-Survivac, the Company’s lead cancer vaccine candidate. Following the presentation of positive Phase I/II clinical trial data at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting earlier this year, the Company plans to advance DPX-Survivac …

Immunovaccine’s Novel Immunotherapy Triggers Partial Response and Generates Potent Immune Responses in Ovarian Cancer Clinical Study

Company to Highlight Promising Clinical Activity of DPX-Survivac Cancer Vaccine at 2014 ASCO Annual Meeting May 20, 2014 Immunovaccine Inc., a clinical stage vaccine company, announced today that new positive clinical data on the Company’s lead cancer vaccine candidate, DPX-Survivac, will be presented as a poster at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June …

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting

Study findings show enhanced therapeutic potential for vaccine when combined with cyclophosphamide and the checkpoint inhibitor anti-PD-1 April 7, 2014 Immunovaccine Inc., a clinical stage vaccine company, presented positive data from clinical and preclinical vaccine studies, including DPX-Survivac, the company’s lead therapeutic cancer vaccine, this weekend at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In a poster …